104261-69-0
Chemical Structure
Homorisedronate
Synonym(s): NE-58051
- CAS No.: 104261-69-0
- Formula:C8H13NO7P2
- Molecular Weight:297.14
IUPAC Name: (1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl)bis(phosphonic acid)
InChIKey: ILROXFQHACCDLA-UHFFFAOYSA-N
SMILES: O=P(O)(C(CCC1=CC=CN=C1)(P(O)(O)=O)O)O
Biological Activity: Homorisedronate (NE-58051) is a MMP inhibitor with high bone mineral affinity but low bone antiresorptive activity in vivo. Homorisedronate inhibits the proteolytic activity of MMP-2, MMP-9, and MMP-12 through zinc chelation and phosphonate groups, with IC50 values of 40 μM, 160 μM, and 80 μM for human MMP-2, mouse MMP-9, and rabbit MMP-12, respectively. Homorisedronate inhibits breast cancer and melanoma cell proliferation without inducing MRONJ-like lesions, altering osteoclast activity, or changing serum TRAcP-5b levels. Homorisedronate is suitable for research related to breast cancer and melanoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Homorisedronate | Homorisedronate (NE-58051) is a MMP inhibitor with high bone mineral affinity but low bone antiresorptive activity in vivo. Homorisedronate inhibits the proteolytic activity of MMP-2, MMP-9, and MMP-12 through zinc chelation and phosphonate groups, with IC50 values of 40 μM, 160 μM, and 80 μM for human MMP-2, mouse MMP-9, and rabbit MMP-12, respectively. Homorisedronate inhibits breast cancer and melanoma cell proliferation without inducing MRONJ-like lesions, altering osteoclast activity, or changing serum TRAcP-5b levels. Homorisedronate is suitable for research related to breast cancer and melanoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kasagawa M, et al. Analysis of Risedronate Analog on Extraction Socket Healing in Mice. In vivo (Athens, Greece). 2025;39(2):648-655. [Content Brief]
- [2]. Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases[J]. Cancer research, 2000, 60(11): 2949-2954.
- [3]. Clézardin P, et al. Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. BoneKEy reports. 2013 Feb 06;2:267.
- [4]. Fournier P G, et al. How do bisphosphonates inhibit bone metastasis in vivo[J]. Neoplasia, 2010, 12(7): 571-578.
